US20200129340A1 - Wound Dressing containing a vacuum pump - Google Patents
Wound Dressing containing a vacuum pump Download PDFInfo
- Publication number
- US20200129340A1 US20200129340A1 US16/602,519 US201916602519A US2020129340A1 US 20200129340 A1 US20200129340 A1 US 20200129340A1 US 201916602519 A US201916602519 A US 201916602519A US 2020129340 A1 US2020129340 A1 US 2020129340A1
- Authority
- US
- United States
- Prior art keywords
- wound
- dressing
- negative pressure
- porous
- sponge material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010052428 Wound Diseases 0.000 claims abstract description 120
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 120
- 239000000463 material Substances 0.000 claims abstract description 80
- 239000012530 fluid Substances 0.000 claims abstract description 36
- 239000000975 dye Substances 0.000 claims abstract description 32
- 230000029663 wound healing Effects 0.000 claims abstract description 10
- 230000003115 biocidal effect Effects 0.000 claims abstract description 7
- 230000037431 insertion Effects 0.000 claims abstract 4
- 238000003780 insertion Methods 0.000 claims abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 4
- 238000007789 sealing Methods 0.000 claims description 26
- 239000011148 porous material Substances 0.000 claims description 22
- 210000000416 exudates and transudate Anatomy 0.000 claims description 19
- 239000001045 blue dye Substances 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 9
- 229960000907 methylthioninium chloride Drugs 0.000 claims description 8
- 238000009792 diffusion process Methods 0.000 claims description 7
- 229920002554 vinyl polymer Polymers 0.000 claims description 7
- 239000001046 green dye Substances 0.000 claims description 6
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005977 Ethylene Substances 0.000 claims description 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 3
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims description 3
- PEJLNXHANOHNSU-UHFFFAOYSA-N acridine-3,6-diamine;10-methylacridin-10-ium-3,6-diamine;chloride Chemical compound [Cl-].C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21.C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 PEJLNXHANOHNSU-UHFFFAOYSA-N 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 230000004888 barrier function Effects 0.000 claims description 3
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical group C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 claims description 3
- 229940107698 malachite green Drugs 0.000 claims description 3
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 claims description 3
- 229960000901 mepacrine Drugs 0.000 claims description 3
- NZYCYASKVWSANA-UHFFFAOYSA-M new methylene blue Chemical compound [Cl-].CCNC1=C(C)C=C2N=C(C=C(C(NCC)=C3)C)C3=[S+]C2=C1 NZYCYASKVWSANA-UHFFFAOYSA-M 0.000 claims description 3
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 claims description 3
- 229920001567 vinyl ester resin Polymers 0.000 claims description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 208000022133 pulmonary valve agenesis Diseases 0.000 abstract 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 27
- 229920002451 polyvinyl alcohol Polymers 0.000 description 27
- 239000006260 foam Substances 0.000 description 21
- 238000009581 negative-pressure wound therapy Methods 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 15
- 230000007246 mechanism Effects 0.000 description 11
- 230000035876 healing Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000005445 natural material Substances 0.000 description 3
- 210000002445 nipple Anatomy 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 241001466453 Laminaria Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 125000004036 acetal group Chemical group 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940010204 binaca Drugs 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006261 foam material Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002906 medical waste Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- -1 polyethylene terephthalate Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 238000002459 porosimetry Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003351 stiffener Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A61F13/00068—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00059—Accessories for dressings provided with visual effects, e.g. printed or colored
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01008—Non-adhesive bandages or dressings characterised by the material
- A61F13/01017—Non-adhesive bandages or dressings characterised by the material synthetic, e.g. polymer based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01021—Non-adhesive bandages or dressings characterised by the structure of the dressing
-
- A61F13/0216—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/05—Bandages or dressings; Absorbent pads specially adapted for use with sub-pressure or over-pressure therapy, wound drainage or wound irrigation, e.g. for use with negative-pressure wound therapy [NPWT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/225—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/58—Adhesives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0029—Radiation
- A61L2/0035—Gamma radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0094—Gaseous substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/08—Radiation
- A61L2/081—Gamma radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/20—Gaseous substances, e.g. vapours
- A61L2/206—Ethylene oxide
-
- A61M1/0003—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00314—Wound bandages with surface treatments
- A61F2013/00336—Wound bandages with surface treatments polymeric resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/42—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators with wetness indicator or alarm
- A61F2013/429—Thermochromic materials, e.g. ink or dye
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
- A61F2013/530481—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having superabsorbent materials, i.e. highly absorbent polymer gel materials
- A61F2013/530583—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having superabsorbent materials, i.e. highly absorbent polymer gel materials characterized by the form
- A61F2013/530649—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having superabsorbent materials, i.e. highly absorbent polymer gel materials characterized by the form in sponge or foam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/21—Pharmaceuticals, e.g. medicaments, artificial body parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/24—Medical instruments, e.g. endoscopes, catheters, sharps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Definitions
- Negative pressure wound therapy has long been used in the treatment of wounds and improves the rate of wound healing while removing fluid, exudates, bacteria and other healing inhibiting substances from the wound site.
- NGWT Negative pressure wound therapy
- Extensive studies of both continuous and intermittent treatment of wounds under negative pressure were conducted in the 1980's and 1990's in various Russian institutions. This testing demonstrated that slow healing wounds healed substantially faster with negative pressure. It was also shown that treatment of wounds with negative pressure produced an antibacterial effect. These studies are described in articles in the Russian medical journal Vestnik Khirurgil. It is believed that such negative pressure wound therapy hastens wound closure by speeding migration of epithelial and subcutaneous tissue adjacent the wound towards the center and away from the base of the wound until the wound closes.
- Negative pressure therapy also known as suction or vacuum therapy has been used in treating and healing wounds.
- Application of negative pressure e.g. reduced or subatmospheric pressure (pressure below normal atmospheric pressure)
- pressure below normal atmospheric pressure e.g. reduced or subatmospheric pressure (pressure below normal atmospheric pressure)
- This technique has proven particularly effective for chronic or healing-resistant wounds, and is also used for other purposes such as post-operative wound care.
- negative pressure wound therapy assists in the closure and healing of many forms of “hard to heal” wounds by reducing tissue edema, encouraging blood flow and granular tissue formation, and/or removing excess exudate and can reduce bacterial load (and thus infection risk).
- negative pressure therapy provides for a wound to be covered to facilitate suction at the wound area.
- a conduit is introduced through the wound covering to provide fluid communication to an external vacuum source.
- Atmospheric gas, wound exudates, or other fluids may thus be drawn from the reservoir through the fluid conduit to stimulate healing of the wound.
- Exudates drawn from the reservoir may be deposited in a collection canister or container.
- U.S. Pat. No. 7,569,742 issued Aug. 4, 2009 discloses a wound dressing apparatus using a micro pump system housed within or above a wound dressing member.
- the micro-pump includes a miniature pump that applies a sub-atmospheric pressure to the wound to draw wound fluid or exudate away from the wound bed while allowing patient mobility.
- U.S. Pat. No. 9,084,845 issued Jul. 21, 2015 discloses a number of pump assemblies for reduced pressure wound therapy which are battery powered.
- the embodiments show a housing, a pump, a flow pathway through the pump, one or more valves in communication with the housing and a one way pressure sensor in communication with a fluid pathway.
- U.S. Pat. No. 9,974,890 issued May 22, 2018 discloses a portable system for sub-atmospheric pressure therapy in connection with healing a surgical wound, including a wound dressing dimensioned for positioning relative to a wound bed of a subject and a sub-atmospheric pressure mechanism carried or worn by the subject.
- the sub-atmospheric pressure mechanism includes a housing having a control unit adapted to draw a vacuum and a canister associated with the housing.
- the canister has a collection bag disposed therein, which is in fluid communication with the wound dressing to receive exudates from the wound bed.
- the collection bag is adapted to expand upon receipt of the fluids and releases gas with operation of the control unit.
- U.S. Pat. No. 10,046,096 issued Aug. 14, 2018 discloses a number of embodiments, some of which have a pump assembly mounted to or supported by a dressing for reduced pressure wound therapy.
- the dressing can have visual pressure, saturation, and/or temperature sensors to provide a visual indication of the level of pressure, saturation, and/or temperature within the dressing.
- the pump assembly can have a controller supported within or by the housing, the controller being configured to control one or more operations of the pump.
- the pump is configured to be sterilized.
- U.S. Patent Application Publication Number 2010/0324510 published Dec. 23, 2010 disclosed a number of embodiments for treating wounds with reduced pressure.
- the preferred device is a sealing film which covers the wound as well as a tube which connects a space over the wound and beneath the sealing film to the negative pressure source which is preferably a pump.
- An open foam hydrophilic material of polyurethane is cut to the shape of the wound to fill the wound pocket. See also U.S. Patent Application Publication Number 2011/0178451 published Jul. 21, 2011 which is directed to foam wound inserts having high density and low density regions which are subjected to negative pressure.
- NGWT Current negative pressure wound therapy
- the SNAP system relies on a mechanical vacuum source and a canister to collect exudate (see U.S. Patent Application Publication Number 2011/0230849 published Sep. 22, 2011), while the PICO system (see U.S. Patent Application Publication Number 2010/0160881 published Jun. 24, 2010) relies on an electrical vacuum source and uses the dressing to collect the exudate.
- a therapeutically useful reduced pressure i.e. vacuum or negative pressure
- the vacuum source is far from the wound bed, creating a need for tubing that is uncomfortable and unsightly for the patient, leading to compliance issues.
- Tubing can be crimped or clogged leading to failure. In sub-freezing climates, the tubing can freeze and as a result, clog leading to failure.
- the pump must reduce the pressure requiring large mechanical or electrical units that can be bulky and noisy. This is further exacerbated by long lengths of tubing that result in greater pressure drop over distance, in turn requiring a larger and more powerful pump.
- a separate wound dressing is used with the prior art negative pressure pumps and the dressing itself is not actively used to treat the wound with natural capillary pressure or kill bacteria, prevent bacteria reproduction or inhibit or destroy biofilm forming within the wound.
- the present invention describes a medical wound dressing device in the field of wound care treatment and is comprised of a porous PVA sponge material dressing having a natural capillary pressure.
- the device is also provided with a biocide.
- the device is also provided with a sealing drape covering the porous PVA sponge dressing material, an auxiliary vacuum generator mechanism such as a negative pressure pump connected to them porous PVA sponge dressing material and a fluid removal path with an optional fluid return path back to the dressing.
- the device enables the application of negative pressure to the porous PVA dressing material and the adjacent wound while covering the wound.
- FIG. 1 is a schematic cross section of the inventive negative pressure wound dressing device
- FIG. 2 is a schematic cross section of another embodiment of the negative pressure wound dressing device
- FIG. 3 is a schematic of the negative pressure provided to the wound dressing of FIGS. 1 and 2 using the inventive wound dressing device.
- FIG. 4 is a schematic of a detailed control circuit of the inventive wound dressing device.
- the present invention is a negative pressure wound therapy (NPWT) system where the reduced atmospheric pressure on the wound is achieved by two sources, (1) a porous sponge dressing material and (2) an auxiliary vacuum unit, e.g. a pump.
- the porous sponge dressing material is a PVA foam which provides a natural capillary pressure of about ⁇ 20 mmHg to about ⁇ 72 mmHg on the wound.
- the auxiliary pump can further reduce the pressure to maintain a therapeutic benefit, e.g. down to about ⁇ 120 mmHg.
- the result is a NPWT system that is portable by the user and is significantly smaller than prior art devices and with minimal to no tubing required to connect the dressing to the auxiliary vacuum source.
- reduced or negative pressure levels represent pressure levels relative to normal ambient atmospheric pressure, which corresponds to 760 mmHg (or 1 atm, 29.93 inHg, 101.325 kPa, 14.696 psi, etc.).
- a negative pressure value of ⁇ X mmHg reflects absolute pressure that is X mmHg below normal ambient atmosphere pressure of 760 mmHg or, in other words, an absolute pressure of (760 mmHg-X mmHg).
- negative pressure that is “less” or “smaller” than the X mmHg negative pressure corresponds to pressure that is closer to atmospheric pressure.
- the present invention describes a medical dressing device for the field of wound care of patients and is comprised of a porous sponge dressing material 10 , preferably PVA foam sponge material 12 , a sealing drape or cover 20 , a fluid removal path 30 , and a vacuum producing mechanism 40 as seen in FIGS. 2 and 4 .
- the device enables the application of negative pressure to a wound with absorption of fluid to the porous sponge dressing material.
- the porous sponge dressing material of the invention is preferably PVA foam sponge material 12 and acts as a source for negative pressure through its natural capillary action and as a wound exudate collection vehicle.
- PVA foam refers to one or more of the following: Polyvinyl formal, Polyvinyl acetal, PVA copolymers of vinyl esters and PVA copolymers of ethylene-containing repeat units. Copolymers with PVA may be random, block, alternating, periodic or graft.
- the acetal group may have one or two substituents such as aliphatic or aromatic groups which may be further substituted.
- Foams may further be comprised of blends of above PVA based polymers with non-PVA polymers.
- porous sponge dressing material is generally referred to by the numeral 10 and the PVA sponge dressing material is referred to by the numeral 12 , these numbers can be interchanged as necessary as both refer to the sponge dressing material.
- the PVA porous dressing material 12 acts as a dressing to the wound surface 14 .
- This material is polymeric in composition where the polymer can be a synthetic substance, a natural substance or combinations thereof.
- the polymer is foamed PVA with positive and negative biocidal dyes which impregnate or bind to the sponge receptor sites.
- the porous PVA sponge dressing material has a morphology characterized by an average pore throat diameter of 10-500 ⁇ m, a fluid retention of 5.5-300 mL fluids/g porous material, a density of 0.05-0.15 g polymer/cm3 porous material, and a porosity of 60-99.5%.
- the cell structure is characterized as open/interconnected with through pores that can be evaluated by techniques such as capillary flow porometry and liquid extrusion porosimetry.
- the natural capillary pressure of the PVA sponge or foam dressing material ranges from about ⁇ 20 mmHg to about ⁇ 70 mmHg. This natural capillary pressure ranges and falls within the low to mid-range settings of presently used mechanical vacuum machines.
- the porous PVA sponge dressing material has one or more material properties which in combination afford fluid flow through the material to create a natural capillary pressure.
- Material properties may include the pore properties above, surface chemical structure, surface roughness and the resultant interfacial tensions arising from the porous PVA material surface and the fluid surface in contact with other.
- Porous PVA materials with natural capillary pressure may be differentiated from porous materials without natural capillary flow by their simplified diffusion coefficient (D) which can be calculated from the general form of the Washburn equation:
- the porous PVA sponge dressing material having natural capillary pressure has a simplified diffusion coefficient greater than 0.3 cm 2 /second; in a more preferred embodiment greater than 0.4 cm 2 /second, and in a most preferred embodiment greater than 0.5 cm 2 /second.
- Table 1 dressings used in the field today have little to no natural capillary pressure as measured by their simplified diffusion coefficient whereas the porous PVA foam of the present invention surprisingly has an almost 4-5 ⁇ ability.
- the simplified diffusion coefficient may be determined to suspending a swatch of the dressing (0.5′′ ⁇ 0.25′′33 3.0′′) in a normal saline solution to allow vertical wicking through the dressing material. Prior to evaluation, all materials are conditioned at ambient temperature for at least 24 hours. The test article is then attached to a suspension fixture and lowered into a test beaker containing saline solution such that one end is slightly submerged in the saline solution. The vertical wicking distance is recorded after 45 seconds. This wicking distance is then corrected to account for the initial height of saline, and the diffusion coefficient is calculated from the corrected wicking distance and wicking time period.
- a biofilm enzymatic solution can also be incorporated into the porous sponge dressing material during the same manufacturing process that binds the antibacterial agents but after addition of the antibacterial agents. During this process, Methylene Blue, Crystal Violet, and biofilm prevention enzyme solution is introduced and allowed to uniformly impregnate or bind to the foam matrix. The product is then dried and processed to final specification and sterilization.
- the porous sponge dressing material may be shaped if desired to be conformable to the shape of the wound bed.
- the porous sponge dressing material may have a surface porosity on the surface distal to the wound that allows for moisture transmission outwards but is impermeable to air (inwards).
- the porous sponge dressing material can self-rejuvenate until it is fully loaded with exudate, up to 5 ⁇ , 10 ⁇ or even 15 ⁇ its weight in exudate fluid, at which time the dressing would be replaced.
- This sponge material of the invention may further be combined with clinically safe agents, e.g. saline, hydration fluids, antimicrobial agents, softening agents, stiffening agents, or wetting agents.
- clinically safe agents e.g. saline, hydration fluids, antimicrobial agents, softening agents, stiffening agents, or wetting agents.
- the agents may be preloaded prior to clinical use or may be loaded by a clinician at the time of clinical use.
- the synthetic polymer can be polyvinyl formal.
- the natural polymer material can be either animal or plant derived, for example, collagen, chitosan, or polyethylene terephthalate.
- the sealing layer, drape or cover 20 acts to form a vacuum seal over the dressing 12 to the wound perimeter.
- the sealing layer 20 may be polymeric in composition where the polymer can be a synthetic substance, a natural substance or combinations thereof.
- the sealing layer may also be metallic in composition.
- the sealing layer may be comprised of multiple polymeric and or metallic layers and may further have adhesives on its surfaces or between layers.
- the vacuum connection assembly 30 acts to apply auxiliary vacuum through the sealing layer 20 to the sponge dressing 12 from the vacuum mechanism 40 via plastic conduits 82 and 80 as seen in FIG. 4 , or nipples 42 as seen in FIG. 2 , or nipple 30 as seen in FIG. 1 .
- the fluid removal assembly (conduit, T-section, nipples) may be polymeric in composition where the polymer can be a synthetic substance, a natural substance or combinations thereof.
- the vacuum connection assembly may also be metallic in composition or a combination of polymer and metal.
- the vacuum connection path may be affixed external to the sealing layer or be imbedded within the sealing layer.
- the medical device described in this invention may be single use and thus disposable or one or more of its components may be reusable. It is envisioned that all components will be disposable and that a whole unit will be disposable as medical waste.
- the device may be fully assembled when received by the customer or may require assembly at the point of care.
- the NPWT system of the invention may optionally have a sealing layer 20 as shown in FIG. 2 on the porous material surface 10 that allows for vapor or moisture transmission outwards but is impermeable to air (inwards).
- the layer 20 is both vapor permeable and an air barrier. As noted above, this would enable the porous sponge material to self-rejuvenate until it is fully loaded with exudate.
- the sealing layer covers only the distal facing porous sponge material surface and abuts the auxiliary vacuum unit.
- the sealing layer extends over the auxiliary vacuum unit, and the vacuum exhaust passes through the sealing layer.
- the sealing layer runs under the auxiliary vacuum unit and the vacuum auxiliary units sits above the sealing layer.
- the sealing layer is translucent to aid in visualization of the porous sponge material by the clinician or patient.
- the inventive assembly may have a vacuum connection component 30 .
- This component would be located between the auxiliary vacuum unit 40 and the foamed porous material dressing 10 / 12 .
- the vacuum connection component has baffles or channels that aid in equilibrating the vacuum from the auxiliary vacuum unit 40 to the porous material 10 / 12 or aid in distributing filtered exudate back to the porous material.
- One or a plurality of fluid removal and/or fluid return chambers may be used where each chamber has one or more of the functions listed above.
- the vacuum connection component may also be provided with a vacuum port/valve.
- This port/valve component is gas permeable but not liquid permeable and acts to protect the auxiliary vacuum unit from being fouled by exudate.
- the assembly may be provided with a check valve to prevent back flow of air into the vacuum connection component and/or the porous sponge material.
- the vacuum connection component may have a length of tubing to separate the auxiliary vacuum unit from the porous sponge material.
- One or a plurality of vacuum port/valves may be used where each unit has one or more of the functions listed above.
- auxiliary vacuum unit 40 can sit on the distal (outward) facing surface of the porous material 10 / 12 , the auxiliary vacuum unit 40 can be embedded or encased in the porous material 10 / 12 to provide a low-profile system.
- the auxiliary vacuum unit 40 may have addition features including:
- the auxiliary vacuum unit 40 is provided with an integral motor 78 and can also be provided with a vacuum exhaust component that allows escape of air and moisture vapor that has traveled through the auxiliary vacuum unit.
- the vacuum exhaust component may sit on the surface of the auxiliary vacuum unit or be attached to the auxiliary vacuum unit through a length of tubing. One or a plurality of vacuum exhausts may be used.
- the auxiliary vacuum unit may also serve as a check valve to prevent back flow of air into the auxiliary vacuum unit.
- the NPWT system may further have a sealing drape layer 20 .
- the sealing drape layer 20 acts to seal the wound bed in an airtight manner. It can also act as the moisture vapor transmission layer described above.
- the sealing layer may cover the auxiliary vacuum unit, porous material and other components of the device.
- the sealing drape layer is non-permeable. In this case it would run from the healthy skin to the moisture vapor transmission layer, or it would still cover the entire NPWT system where moisture transmission would be through the auxiliary vacuum unit or vacuum exhaust component.
- the control system 70 as schematically shown in FIG. 4 comprises a low power microcontroller 71 , a three LED indicators 72 , one or more push button switches 74 , ambient 76 a and vacuum 76 b pressure sensors, a vacuum motor 78 , motor power control 79 , one or more batteries 77 and a tactile feedback device 72 a .
- the vacuum pressure sensor has a “T” attachment 82 connecting it to the plastic conduit 80 (for vacuum connection component 30 ) which connects the vacuum motor to the wound dressing 10 placed on the patient wound 14 .
- the ambient pressure sensor 76 a is open to the atmosphere.
- the microcontroller implents the logic described herein with the C source code language compiled and downloaded for execution to the microcontroller.
- the clinically therapeutic negative pressure range for the device is about ⁇ 60 mmHg to about ⁇ 120 mmHg which is shown in FIG. 3 by the letter R.
- a normal working cycle is shown in FIG. 3 .
- the ramp up is shown by the letter A and the decay is shown by the letter D.
- the negative pressure should fall within about ⁇ 80 mmHg to about ⁇ 100 mmHg and most preferably about ⁇ 85 mmHg to about ⁇ 95 mmHg.
- the negative pressure cut-off value for the device is about ⁇ 120 mmHg. Beyond this value, the patient experiences discomfort.
- the push button and three LED ⁇ circumflex over ( ) ⁇ s provide the device user interface.
- the push button When the push button is first pushed, the device starts up, performs an initial operational check and indicates it is ready for operation by illuminating a green LED.
- the second time the push button is pushed the device initiates treatment and starts monitoring operational status.
- Good status is indicated by an illuminated green light.
- Warning status is indicated by an illuminated yellow light and a unique tactile feedback pattern. Error status is indicated by an illuminated red light and a different unique tactile feedback pattern.
- Differential pressure sensors require that the path to the ambient pressure be physically adjacent to the path to the vacuum pressure. Separate sensors allow the paths to be physically separated. Differential pressure sensors are bulky and difficult to mount, whereas absolute pressure sensors are small with a wide variety at mounting options.
- the ambient pressure sensor provides barometric pressure, which can provide an input to the volume calculations to determine the operational status.
- the device undergoes initial start-up.
- the vacuum motor 78 will turn on and remain running until it reaches the upper therapy threshold, at which point the vacuum motor is turned off and the pressure control will start.
- Pressure control consists of reading the ambient and vacuum pressure sensors periodically. Each time a sensor is read, the vacuum level is calculated as the difference between the ambient and vacuum pressure sensors. If the vacuum is at or below the lower therapy threshold, the vacuum motor is turned on. When the vacuum subsequently reaches the upper therapy threshold, the vacuum motor is turned off.
- variable vacuum level may provide more effective therapy than a constant vacuum level.
- the microcontroller may optionally change the upper and lower threshold values in a redetermined pattern over the course of several minutes to improve the therapy effectiveness.
- the pressure is held constant.
- Operational status monitoring will run continuously once the NPWT device is started with the first push of the button.
- the status monitoring will include battery level, leak detection, microcontroller health, blockage detection, loss of volume capacity and device lifetime.
- the battery level will be monitored using both coulomb counting methods, and voltage level measurements.
- a warning level and error level will be established for battery monitoring based on battery characteristics. Leak rate will be calculated by summing the time of the ramp up (A in FIG. 3 ) over a known time combined with the vacuum pump characteristics.
- the warning level will be established based on a projection of the loss of 20% of the lifetime of the device.
- the error level will be the point where the device is no longer able to maintain the pressure above the lower therapy threshold or the projected lifetime of the device due to the leak is less than 12 hours.
- the microcontroller health will be monitored by a hardware watchdog, which will turn off the device if the microcontroller does not run the pressure control logic at the selected periodic rate.
- the microprocessor will track the elapsed time that the NPWT has provided therapy. When the elapsed time is within 12 hours of a predetermined lifetime, the device will shut down the therapy, and turn off all the indicator LED's.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
- This is a utility patent application claiming priority and benefit from U.S. Provisional Patent Application No. 62/749,902 filed Oct. 24, 2018.
- None
- None.
- The present invention is directed toward a PVA wound dressing for the treatment of wounds containing a pump which administers negative pressure to the wound site.
- Negative pressure wound therapy (NPWT) has long been used in the treatment of wounds and improves the rate of wound healing while removing fluid, exudates, bacteria and other healing inhibiting substances from the wound site. Extensive studies of both continuous and intermittent treatment of wounds under negative pressure were conducted in the 1980's and 1990's in various Russian institutions. This testing demonstrated that slow healing wounds healed substantially faster with negative pressure. It was also shown that treatment of wounds with negative pressure produced an antibacterial effect. These studies are described in articles in the Russian medical journal Vestnik Khirurgil. It is believed that such negative pressure wound therapy hastens wound closure by speeding migration of epithelial and subcutaneous tissue adjacent the wound towards the center and away from the base of the wound until the wound closes.
- Negative pressure therapy also known as suction or vacuum therapy has been used in treating and healing wounds. Application of negative pressure, e.g. reduced or subatmospheric pressure (pressure below normal atmospheric pressure), to a localized reservoir over a wound has been found to assist in closing the wound by promoting blood flow to the area, stimulating the formation of granulation tissue, and encouraging the migration of healthy tissue over the wound. This technique has proven particularly effective for chronic or healing-resistant wounds, and is also used for other purposes such as post-operative wound care.
- Thus it is known that negative pressure wound therapy assists in the closure and healing of many forms of “hard to heal” wounds by reducing tissue edema, encouraging blood flow and granular tissue formation, and/or removing excess exudate and can reduce bacterial load (and thus infection risk).
- Generally, negative pressure therapy provides for a wound to be covered to facilitate suction at the wound area. A conduit is introduced through the wound covering to provide fluid communication to an external vacuum source. Atmospheric gas, wound exudates, or other fluids may thus be drawn from the reservoir through the fluid conduit to stimulate healing of the wound. Exudates drawn from the reservoir may be deposited in a collection canister or container.
- U.S. Pat. No. 3,572,340 issued Mar. 23, 1971 discloses a pump in the form of an elastically compressible body made of an open celled foam material, preferably polyurethane foam which body also serves as a receptacle for fluid drained from a wound. The pump is said to have a capacity to maintain a negative pressure of 15-80 mmHg for over 48 hours. A drain placed in the wound pocket and is connected to the pump by a tube.
- See also U.S. Pat. No. 4,525,166 issued Jun. 25, 1985 which uses laminaria (kelp) instead of foam. Laminaria swells by absorption of liquid and does not release the liquid.
- U.S. Pat. No. 7,569,742 issued Aug. 4, 2009 discloses a wound dressing apparatus using a micro pump system housed within or above a wound dressing member. The micro-pump includes a miniature pump that applies a sub-atmospheric pressure to the wound to draw wound fluid or exudate away from the wound bed while allowing patient mobility.
- U.S. Pat. No. 9,084,845 issued Jul. 21, 2015 discloses a number of pump assemblies for reduced pressure wound therapy which are battery powered. The embodiments show a housing, a pump, a flow pathway through the pump, one or more valves in communication with the housing and a one way pressure sensor in communication with a fluid pathway.
- In U.S. Pat. No. 9,974,890 issued May 22, 2018 discloses a portable system for sub-atmospheric pressure therapy in connection with healing a surgical wound, including a wound dressing dimensioned for positioning relative to a wound bed of a subject and a sub-atmospheric pressure mechanism carried or worn by the subject. The sub-atmospheric pressure mechanism includes a housing having a control unit adapted to draw a vacuum and a canister associated with the housing. The canister has a collection bag disposed therein, which is in fluid communication with the wound dressing to receive exudates from the wound bed. The collection bag is adapted to expand upon receipt of the fluids and releases gas with operation of the control unit.
- U.S. Pat. No. 10,046,096 issued Aug. 14, 2018 discloses a number of embodiments, some of which have a pump assembly mounted to or supported by a dressing for reduced pressure wound therapy. The dressing can have visual pressure, saturation, and/or temperature sensors to provide a visual indication of the level of pressure, saturation, and/or temperature within the dressing. The pump assembly can have a controller supported within or by the housing, the controller being configured to control one or more operations of the pump. The pump is configured to be sterilized.
- U.S. Patent Application Publication Number 2010/0324510 published Dec. 23, 2010 disclosed a number of embodiments for treating wounds with reduced pressure. The preferred device is a sealing film which covers the wound as well as a tube which connects a space over the wound and beneath the sealing film to the negative pressure source which is preferably a pump. An open foam hydrophilic material of polyurethane is cut to the shape of the wound to fill the wound pocket. See also U.S. Patent Application Publication Number 2011/0178451 published Jul. 21, 2011 which is directed to foam wound inserts having high density and low density regions which are subjected to negative pressure.
- Current negative pressure wound therapy (NPWT) systems are generally comprised of a wound dressing, a canister to collect wound exudate, and a pump or a vacuum source. The SNAP system relies on a mechanical vacuum source and a canister to collect exudate (see U.S. Patent Application Publication Number 2011/0230849 published Sep. 22, 2011), while the PICO system (see U.S. Patent Application Publication Number 2010/0160881 published Jun. 24, 2010) relies on an electrical vacuum source and uses the dressing to collect the exudate. In these cases, a therapeutically useful reduced pressure (i.e. vacuum or negative pressure) is achieved through the vacuum source.
- There are numerous problems with the current prior art. The vacuum source is far from the wound bed, creating a need for tubing that is uncomfortable and unsightly for the patient, leading to compliance issues. Tubing can be crimped or clogged leading to failure. In sub-freezing climates, the tubing can freeze and as a result, clog leading to failure. The pump must reduce the pressure requiring large mechanical or electrical units that can be bulky and noisy. This is further exacerbated by long lengths of tubing that result in greater pressure drop over distance, in turn requiring a larger and more powerful pump. A separate wound dressing is used with the prior art negative pressure pumps and the dressing itself is not actively used to treat the wound with natural capillary pressure or kill bacteria, prevent bacteria reproduction or inhibit or destroy biofilm forming within the wound.
- The present invention describes a medical wound dressing device in the field of wound care treatment and is comprised of a porous PVA sponge material dressing having a natural capillary pressure. The device is also provided with a biocide. The device is also provided with a sealing drape covering the porous PVA sponge dressing material, an auxiliary vacuum generator mechanism such as a negative pressure pump connected to them porous PVA sponge dressing material and a fluid removal path with an optional fluid return path back to the dressing. The device enables the application of negative pressure to the porous PVA dressing material and the adjacent wound while covering the wound.
- It is an object of the invention to provide a constant source of low negative pressure on the wound through the natural capillary pressure of the porous sponge dressing material while systematically providing a second higher negative pressure on the wound by applying a secondary negative pressure.
- It is another object of the invention to provide a natural capillary pressure wound dressing material to a wound and applying additional negative pressure to the dressing material and wound by a vacuum mechanism which heals and closes a wound in quicker time than conventional wound dressings.
- It is still another object of the invention to provide a wound dressing material having a natural capillary pressure and providing additional mechanical negative pressure to the dressing material which is superior to only mechanically produced negative pressure application to a wound.
- It is another object of the invention to provide a wound dressing device which is disposable;
- It is yet another object of the invention to provide a wound dressing device which is easier to apply to the user;
- It is another object of the invention to provide a continuous operational status to the user and alert the user of any operational problem with the device with visual and tactile indicators; and
- It is still another object of the invention to provide a self-contained wound dressing device that can be easily carried by the patient being treated.
- The present invention will be described with reference to the appended Figures, in which:
-
FIG. 1 is a schematic cross section of the inventive negative pressure wound dressing device; -
FIG. 2 is a schematic cross section of another embodiment of the negative pressure wound dressing device; -
FIG. 3 is a schematic of the negative pressure provided to the wound dressing ofFIGS. 1 and 2 using the inventive wound dressing device; and -
FIG. 4 is a schematic of a detailed control circuit of the inventive wound dressing device. - These and other objects, advantages, and novel features of the present invention will become apparent when considered with the teachings contained in the detailed disclosure along with the accompanying drawings.
- The present invention is a negative pressure wound therapy (NPWT) system where the reduced atmospheric pressure on the wound is achieved by two sources, (1) a porous sponge dressing material and (2) an auxiliary vacuum unit, e.g. a pump. The porous sponge dressing material is a PVA foam which provides a natural capillary pressure of about −20 mmHg to about −72 mmHg on the wound. The auxiliary pump can further reduce the pressure to maintain a therapeutic benefit, e.g. down to about −120 mmHg. The result is a NPWT system that is portable by the user and is significantly smaller than prior art devices and with minimal to no tubing required to connect the dressing to the auxiliary vacuum source.
- As is used herein, reduced or negative pressure levels, such as −X mmHg, represent pressure levels relative to normal ambient atmospheric pressure, which corresponds to 760 mmHg (or 1 atm, 29.93 inHg, 101.325 kPa, 14.696 psi, etc.). Accordingly, a negative pressure value of −X mmHg reflects absolute pressure that is X mmHg below normal ambient atmosphere pressure of 760 mmHg or, in other words, an absolute pressure of (760 mmHg-X mmHg). In addition, negative pressure that is “less” or “smaller” than the X mmHg negative pressure corresponds to pressure that is closer to atmospheric pressure.
- The present invention describes a medical dressing device for the field of wound care of patients and is comprised of a porous sponge dressing material 10, preferably PVA foam sponge material 12, a sealing drape or cover 20, a
fluid removal path 30, and avacuum producing mechanism 40 as seen inFIGS. 2 and 4 . The device enables the application of negative pressure to a wound with absorption of fluid to the porous sponge dressing material. - The porous sponge dressing material of the invention is preferably PVA foam sponge material 12 and acts as a source for negative pressure through its natural capillary action and as a wound exudate collection vehicle. The term PVA foam refers to one or more of the following: Polyvinyl formal, Polyvinyl acetal, PVA copolymers of vinyl esters and PVA copolymers of ethylene-containing repeat units. Copolymers with PVA may be random, block, alternating, periodic or graft. The acetal group may have one or two substituents such as aliphatic or aromatic groups which may be further substituted. Foams may further be comprised of blends of above PVA based polymers with non-PVA polymers. The porous PVA sponge 12 has a surface chemistry and porosity that create capillary flow properties, which in turn provide for a natural capillary pressure leading to exudate being drawn from the wound into the porous material. The reduced pressure created by the capillary action of the porous material enables the auxiliary vacuum unit or
vacuum producing mechanism 40 as shown inFIGS. 1 and 2 to do less work, thereby affording smaller and less energy consuming technologies to be employed over current commercial products. - While the porous sponge dressing material is generally referred to by the numeral 10 and the PVA sponge dressing material is referred to by the numeral 12, these numbers can be interchanged as necessary as both refer to the sponge dressing material.
- The PVA porous dressing material 12 acts as a dressing to the
wound surface 14. This material is polymeric in composition where the polymer can be a synthetic substance, a natural substance or combinations thereof. In the preferred embodiment, the polymer is foamed PVA with positive and negative biocidal dyes which impregnate or bind to the sponge receptor sites. The porous PVA sponge dressing material has a morphology characterized by an average pore throat diameter of 10-500 μm, a fluid retention of 5.5-300 mL fluids/g porous material, a density of 0.05-0.15 g polymer/cm3 porous material, and a porosity of 60-99.5%. The cell structure is characterized as open/interconnected with through pores that can be evaluated by techniques such as capillary flow porometry and liquid extrusion porosimetry. The natural capillary pressure of the PVA sponge or foam dressing material ranges from about −20 mmHg to about −70 mmHg. This natural capillary pressure ranges and falls within the low to mid-range settings of presently used mechanical vacuum machines. - Without wishing to be bound by theory, the porous PVA sponge dressing material has one or more material properties which in combination afford fluid flow through the material to create a natural capillary pressure. Material properties may include the pore properties above, surface chemical structure, surface roughness and the resultant interfacial tensions arising from the porous PVA material surface and the fluid surface in contact with other. Porous PVA materials with natural capillary pressure may be differentiated from porous materials without natural capillary flow by their simplified diffusion coefficient (D) which can be calculated from the general form of the Washburn equation:
-
-
- where (L) is the wicking distance of the liquid at time (t).
- In a preferred embodiment the porous PVA sponge dressing material having natural capillary pressure has a simplified diffusion coefficient greater than 0.3 cm2/second; in a more preferred embodiment greater than 0.4 cm2/second, and in a most preferred embodiment greater than 0.5 cm2/second. As shown in Table 1, dressings used in the field today have little to no natural capillary pressure as measured by their simplified diffusion coefficient whereas the porous PVA foam of the present invention surprisingly has an almost 4-5× ability.
-
TABLE 1 Negative Pressure Wound Therapy Negative Diffusion Coefficient Dressing (cm2/s) KCISNAP Dressing 0.00 KCIVAC Whiteman 0.00 Cork Medical NPWT Black Foam 0.00 Cardinal Health NPWT Black Foam 0.00 GelTex NFWI Dressing 0.00 DeRoyal Top Draw Black 0.00 Porous PVA Foam 0.98 - The simplified diffusion coefficient may be determined to suspending a swatch of the dressing (0.5″×0.25″33 3.0″) in a normal saline solution to allow vertical wicking through the dressing material. Prior to evaluation, all materials are conditioned at ambient temperature for at least 24 hours. The test article is then attached to a suspension fixture and lowered into a test beaker containing saline solution such that one end is slightly submerged in the saline solution. The vertical wicking distance is recorded after 45 seconds. This wicking distance is then corrected to account for the initial height of saline, and the diffusion coefficient is calculated from the corrected wicking distance and wicking time period.
- A biofilm enzymatic solution can also be incorporated into the porous sponge dressing material during the same manufacturing process that binds the antibacterial agents but after addition of the antibacterial agents. During this process, Methylene Blue, Crystal Violet, and biofilm prevention enzyme solution is introduced and allowed to uniformly impregnate or bind to the foam matrix. The product is then dried and processed to final specification and sterilization.
- The porous sponge dressing material may further have agents that bind and/or eliminate toxins from the exudate, e.g. bacteria, mold, spores, endotoxins. The present invention uses foamed polyvinyl alcohol which is treated to open up the binding sites of the foam. The washed foam is soaked with one or more gram positive dyes selected from a group of dyes consisting of Gentian Violet dye, also called Crystal Violet dye, Malachite Green dye, Brilliant Green dye, Quinacrine dye and Acriflavin dye and one or more gram negative dyes selected from a group of dyes consisting of Methylene Blue dye, Dimethyl Methylene Blue dye, New Methylene Blue dye. The preferred dyes used in the invention are Methylene Blue dye and Gentian or Crystal Violet dye are attached to a finite number of the binding sites in the foam. Generally, electronegative (acidic) dyes are more effective on Gram-negative bacteria and electropositive (basic) dyes are more effective on Gram positive bacteria such as Staphyloccus aureus.
- The porous sponge dressing material may be shaped if desired to be conformable to the shape of the wound bed. The porous sponge dressing material may have a surface porosity on the surface distal to the wound that allows for moisture transmission outwards but is impermeable to air (inwards). As a result, the porous sponge dressing material can self-rejuvenate until it is fully loaded with exudate, up to 5×, 10× or even 15× its weight in exudate fluid, at which time the dressing would be replaced.
- This sponge material of the invention may further be combined with clinically safe agents, e.g. saline, hydration fluids, antimicrobial agents, softening agents, stiffening agents, or wetting agents. The agents may be preloaded prior to clinical use or may be loaded by a clinician at the time of clinical use.
- In another example, the synthetic polymer can be polyvinyl formal. The natural polymer material can be either animal or plant derived, for example, collagen, chitosan, or polyethylene terephthalate.
- The sealing layer, drape or cover 20 acts to form a vacuum seal over the dressing 12 to the wound perimeter. The
sealing layer 20 may be polymeric in composition where the polymer can be a synthetic substance, a natural substance or combinations thereof. The sealing layer may also be metallic in composition. The sealing layer may be comprised of multiple polymeric and or metallic layers and may further have adhesives on its surfaces or between layers. - The
vacuum connection assembly 30 acts to apply auxiliary vacuum through thesealing layer 20 to the sponge dressing 12 from thevacuum mechanism 40 viaplastic conduits FIG. 4 , ornipples 42 as seen inFIG. 2 , ornipple 30 as seen inFIG. 1 . The fluid removal assembly (conduit, T-section, nipples) may be polymeric in composition where the polymer can be a synthetic substance, a natural substance or combinations thereof. The vacuum connection assembly may also be metallic in composition or a combination of polymer and metal. The vacuum connection path may be affixed external to the sealing layer or be imbedded within the sealing layer. - The
vacuum mechanism 40 provides a clinically beneficial negative pressure (up to −120 mm Hg) to thewound site 14 through the porous foam dressing material 10/12. Thevacuum mechanism 40 may be affixed external to thesealing layer 20, positioned adjacent the sealing layer or be imbedded within the sealing layer and draws fluid away from the porous foam sponge material through one or more paths. The vacuum or negative pressure is achieved and controlled through many methods known to those skilled in the art. In one embodiment, the vacuum is achieved through an energized device. In another embodiment, the vacuum is achieved through a manual process such as a syringe or squeeze bulb. Preferably, the device is a mechanical pump which is energized or powered by batteries. The vacuum mechanism may allow for filtration of fluid prior to entering the fluid return path. The vacuum mechanism may allow for the addition of clinically safe agents to the fluid prior to entering the fluid return path. - The medical device described in this invention may be single use and thus disposable or one or more of its components may be reusable. It is envisioned that all components will be disposable and that a whole unit will be disposable as medical waste. The device may be fully assembled when received by the customer or may require assembly at the point of care.
- The NPWT system of the invention may optionally have a
sealing layer 20 as shown inFIG. 2 on the porous material surface 10 that allows for vapor or moisture transmission outwards but is impermeable to air (inwards). In other words, thelayer 20 is both vapor permeable and an air barrier. As noted above, this would enable the porous sponge material to self-rejuvenate until it is fully loaded with exudate. In one embodiment, the sealing layer covers only the distal facing porous sponge material surface and abuts the auxiliary vacuum unit. In another embodiment, the sealing layer extends over the auxiliary vacuum unit, and the vacuum exhaust passes through the sealing layer. In yet another embodiment, the sealing layer runs under the auxiliary vacuum unit and the vacuum auxiliary units sits above the sealing layer. In a preferred embodiment, the sealing layer is translucent to aid in visualization of the porous sponge material by the clinician or patient. - As previously noted, the inventive assembly may have a
vacuum connection component 30. This component would be located between theauxiliary vacuum unit 40 and the foamed porous material dressing 10/12. In one embodiment of the invention, the vacuum connection component has baffles or channels that aid in equilibrating the vacuum from theauxiliary vacuum unit 40 to the porous material 10/12 or aid in distributing filtered exudate back to the porous material. One or a plurality of fluid removal and/or fluid return chambers may be used where each chamber has one or more of the functions listed above. - The vacuum connection component may also be provided with a vacuum port/valve. This port/valve component is gas permeable but not liquid permeable and acts to protect the auxiliary vacuum unit from being fouled by exudate. In another embodiment, the assembly may be provided with a check valve to prevent back flow of air into the vacuum connection component and/or the porous sponge material. In yet another embodiment, the vacuum connection component may have a length of tubing to separate the auxiliary vacuum unit from the porous sponge material. One or a plurality of vacuum port/valves may be used where each unit has one or more of the functions listed above.
- The
auxiliary vacuum unit 40 of the invention (seevacuum motor 78 inFIG. 4 ) supplements the negative pressure provided by the foam porous dressing material 12 so that the total negative pressure on the wound remains in a clinically beneficial range. In one example (FIG. 3 ), the porous material 12 alone provides negative pressure that is above the clinically beneficial threshold, and the auxiliary unit supplements that pressure by raising the pressure higher in the therapeutic range. As exudate is drawn into the foam porous dressing material 12, air or moisture exhaust from the system and/or leaks occur in the system, the pump can apply vacuum to maintain the therapeutic range. As the porous material gets filled, its contribution to maintenance of the therapeutically beneficial negative pressure decreases and the auxiliary vacuum unit's contribution increases. When the porous material is fully saturated, and/or the auxiliary vacuum no longer has power sufficient to hold a therapeutic negative pressure, the NPWT system can be replaced with a new device. It should be recognized that the system's design allows for different ratios of negative pressure contribution from the porous material and auxiliary vacuum unit, and that the ratio may vary over the course of the treatment period. - As previously noted, the auxiliary vacuum unit can be powered by a mechanical action, e.g. a syringe force. The auxiliary vacuum unit (pump) is preferably powered with an electrical supply, most preferably a battery. Examples of battery powered pumps that could be used in the auxiliary vacuum unit include Models Compact/OEM and KPV-14A available from Cole Parmer, Model NMP 03 KP DC-S available from KNF Neuberger, Inc. and Model SX-1 from Binaca Products.
- While the
auxiliary vacuum unit 40 can sit on the distal (outward) facing surface of the porous material 10/12, theauxiliary vacuum unit 40 can be embedded or encased in the porous material 10/12 to provide a low-profile system. - The
auxiliary vacuum unit 40 may have addition features including: -
- Pressure feedback loop enabling constant pressure adjustment
- Pressure feedback loop enabling intermittent pressure adjustment (cycling)
- Pressure cut off detection when pressure is beyond therapeutic level
- Leak detection when pressure decay is too rapid
- Pressure ramp up detection when rate (mm Hg/sec) of pressure increase is too steep, indicating the porous material or fluid removal/fluid return chamber is saturated or exhausted
- Total pressure reduction in a cycle, which when above a threshold, indicates the porous material or fluid removal/fluid return chamber is saturated or exhausted
- The
auxiliary vacuum unit 40 is provided with anintegral motor 78 and can also be provided with a vacuum exhaust component that allows escape of air and moisture vapor that has traveled through the auxiliary vacuum unit. The vacuum exhaust component may sit on the surface of the auxiliary vacuum unit or be attached to the auxiliary vacuum unit through a length of tubing. One or a plurality of vacuum exhausts may be used. The auxiliary vacuum unit may also serve as a check valve to prevent back flow of air into the auxiliary vacuum unit. - The NPWT system may further have a sealing
drape layer 20. The sealingdrape layer 20 acts to seal the wound bed in an airtight manner. It can also act as the moisture vapor transmission layer described above. In this case, the sealing layer may cover the auxiliary vacuum unit, porous material and other components of the device. In another modification, the sealing drape layer is non-permeable. In this case it would run from the healthy skin to the moisture vapor transmission layer, or it would still cover the entire NPWT system where moisture transmission would be through the auxiliary vacuum unit or vacuum exhaust component. - The overall system is a single use, disposable product. The system is supplied sterile and have a useful lifetime of approximately 1 day, more preferably 2-3 days, and most preferably up to 7 days depending upon the type and severity of the wound.
- The
control system 70 as schematically shown inFIG. 4 comprises alow power microcontroller 71, a threeLED indicators 72, one or more push button switches 74, ambient 76 a andvacuum 76 b pressure sensors, avacuum motor 78,motor power control 79, one ormore batteries 77 and atactile feedback device 72 a. The vacuum pressure sensor has a “T”attachment 82 connecting it to the plastic conduit 80 (for vacuum connection component 30) which connects the vacuum motor to the wound dressing 10 placed on the patient wound 14. Theambient pressure sensor 76 a is open to the atmosphere. The microcontroller implents the logic described herein with the C source code language compiled and downloaded for execution to the microcontroller. - The clinically therapeutic negative pressure range for the device is about −60 mmHg to about −120 mmHg which is shown in
FIG. 3 by the letter R. A normal working cycle is shown inFIG. 3 . The ramp up is shown by the letter A and the decay is shown by the letter D. However, it is preferred that the negative pressure should fall within about −80 mmHg to about −100 mmHg and most preferably about −85 mmHg to about −95 mmHg. - The negative pressure cut-off value for the device is about −120 mmHg. Beyond this value, the patient experiences discomfort.
- The push button and three LED{circumflex over ( )}s provide the device user interface. When the push button is first pushed, the device starts up, performs an initial operational check and indicates it is ready for operation by illuminating a green LED. The second time the push button is pushed, the device initiates treatment and starts monitoring operational status. Good status is indicated by an illuminated green light. Warning status is indicated by an illuminated yellow light and a unique tactile feedback pattern. Error status is indicated by an illuminated red light and a different unique tactile feedback pattern.
- Having separate ambient and vacuum absolute pressure sensors have advantages over a single differential sensor common the state of the art. Differential pressure sensors require that the path to the ambient pressure be physically adjacent to the path to the vacuum pressure. Separate sensors allow the paths to be physically separated. Differential pressure sensors are bulky and difficult to mount, whereas absolute pressure sensors are small with a wide variety at mounting options. The ambient pressure sensor provides barometric pressure, which can provide an input to the volume calculations to determine the operational status.
- At the onset of treatment with the dressing properly secured with no leaks, the device undergoes initial start-up. The
vacuum motor 78 will turn on and remain running until it reaches the upper therapy threshold, at which point the vacuum motor is turned off and the pressure control will start. - Pressure control consists of reading the ambient and vacuum pressure sensors periodically. Each time a sensor is read, the vacuum level is calculated as the difference between the ambient and vacuum pressure sensors. If the vacuum is at or below the lower therapy threshold, the vacuum motor is turned on. When the vacuum subsequently reaches the upper therapy threshold, the vacuum motor is turned off.
- Research has shown that a variable vacuum level may provide more effective therapy than a constant vacuum level. During the course of therapy, the microcontroller may optionally change the upper and lower threshold values in a redetermined pattern over the course of several minutes to improve the therapy effectiveness. In another embodiment, the pressure is held constant.
- Operational status monitoring will run continuously once the NPWT device is started with the first push of the button. The status monitoring will include battery level, leak detection, microcontroller health, blockage detection, loss of volume capacity and device lifetime. The battery level will be monitored using both coulomb counting methods, and voltage level measurements. A warning level and error level will be established for battery monitoring based on battery characteristics. Leak rate will be calculated by summing the time of the ramp up (A in
FIG. 3 ) over a known time combined with the vacuum pump characteristics. The warning level will be established based on a projection of the loss of 20% of the lifetime of the device. The error level will be the point where the device is no longer able to maintain the pressure above the lower therapy threshold or the projected lifetime of the device due to the leak is less than 12 hours. The microcontroller health will be monitored by a hardware watchdog, which will turn off the device if the microcontroller does not run the pressure control logic at the selected periodic rate. The microprocessor will track the elapsed time that the NPWT has provided therapy. When the elapsed time is within 12 hours of a predetermined lifetime, the device will shut down the therapy, and turn off all the indicator LED's. - The principles, preferred embodiments and modes of operation of the present invention have been described in the foregoing specification. However, the invention should not be construed as limited to the particular embodiments which have been described above. Instead, the embodiments described here should be regarded as illustrative rather than restrictive. Variations and changes may be made by others without departing from the scope of the present invention as defined by the following claims:
Claims (24)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/602,519 US20200129340A1 (en) | 2018-10-24 | 2019-10-24 | Wound Dressing containing a vacuum pump |
US18/196,079 US20230310219A1 (en) | 2018-10-24 | 2023-05-11 | Wound dressing containing a vacuum pump |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862749902P | 2018-10-24 | 2018-10-24 | |
US16/602,519 US20200129340A1 (en) | 2018-10-24 | 2019-10-24 | Wound Dressing containing a vacuum pump |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/196,079 Continuation US20230310219A1 (en) | 2018-10-24 | 2023-05-11 | Wound dressing containing a vacuum pump |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200129340A1 true US20200129340A1 (en) | 2020-04-30 |
Family
ID=70326172
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/602,439 Abandoned US20200129339A1 (en) | 2018-10-24 | 2019-10-07 | Sterilization of medical devices with enhanced antimicrobial properties |
US16/602,440 Abandoned US20200129648A1 (en) | 2018-10-24 | 2019-10-07 | Sterilization of Medical Dressings with Enhanced Antimicrobial Properties |
US16/602,519 Abandoned US20200129340A1 (en) | 2018-10-24 | 2019-10-24 | Wound Dressing containing a vacuum pump |
US18/196,079 Pending US20230310219A1 (en) | 2018-10-24 | 2023-05-11 | Wound dressing containing a vacuum pump |
US18/198,469 Pending US20230285197A1 (en) | 2018-10-24 | 2023-05-17 | Sterilization of medical dressings with enhanced antimicrobial properties |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/602,439 Abandoned US20200129339A1 (en) | 2018-10-24 | 2019-10-07 | Sterilization of medical devices with enhanced antimicrobial properties |
US16/602,440 Abandoned US20200129648A1 (en) | 2018-10-24 | 2019-10-07 | Sterilization of Medical Dressings with Enhanced Antimicrobial Properties |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/196,079 Pending US20230310219A1 (en) | 2018-10-24 | 2023-05-11 | Wound dressing containing a vacuum pump |
US18/198,469 Pending US20230285197A1 (en) | 2018-10-24 | 2023-05-17 | Sterilization of medical dressings with enhanced antimicrobial properties |
Country Status (1)
Country | Link |
---|---|
US (5) | US20200129339A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112998950A (en) * | 2021-03-29 | 2021-06-22 | 张梦蝶 | Medical treatment is with filler equipment of dressing sponge ring |
WO2024117756A1 (en) * | 2022-11-30 | 2024-06-06 | (주)시지바이오 | Negative pressure therapy device and method for controlling same |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0808376D0 (en) | 2008-05-08 | 2008-06-18 | Bristol Myers Squibb Co | Wound dressing |
GB201020236D0 (en) | 2010-11-30 | 2011-01-12 | Convatec Technologies Inc | A composition for detecting biofilms on viable tissues |
WO2012078781A1 (en) | 2010-12-08 | 2012-06-14 | Convatec Technologies Inc. | Integrated system for assessing wound exudates |
ES2748519T3 (en) | 2010-12-08 | 2020-03-17 | Convatec Technologies Inc | Wound exudate system accessory |
GB2497406A (en) | 2011-11-29 | 2013-06-12 | Webtec Converting Llc | Dressing with a perforated binder layer |
EP2935688A2 (en) | 2012-12-20 | 2015-10-28 | ConvaTec Technologies Inc. | Processing of chemically modified cellulosic fibres |
US11596554B2 (en) | 2016-07-08 | 2023-03-07 | Convatec Technologies Inc. | Flexible negative pressure system |
CA3030153C (en) | 2016-07-08 | 2023-10-24 | Convatec Technologies Inc. | Fluid flow sensing |
BR112019000284A2 (en) | 2016-07-08 | 2019-04-16 | Convatec Technologies Inc. | fluid collection apparatus |
US11771819B2 (en) | 2019-12-27 | 2023-10-03 | Convatec Limited | Low profile filter devices suitable for use in negative pressure wound therapy systems |
US11331221B2 (en) | 2019-12-27 | 2022-05-17 | Convatec Limited | Negative pressure wound dressing |
IL306013A (en) * | 2021-03-24 | 2023-11-01 | Kerecis Hf | A colored biologic wound treatment providing healing progress monitoring |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020114826A1 (en) * | 2001-02-21 | 2002-08-22 | Drury Thomas J. | PVA sponge with low durometer skin silicone |
US20120157750A1 (en) * | 2010-12-15 | 2012-06-21 | Timothy Mark Robinson | Targeted Delivery of Magnetically Tagged Active Agents in Combination with Negative Pressure Wound Therapy |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE505000C2 (en) * | 1996-05-14 | 1997-06-09 | Moelnlycke Ab | Wound dressing and manufacturing process therefore |
US5811471A (en) * | 1997-09-15 | 1998-09-22 | Shanbrom Technologies Llc | Disinfectant plastic sponge material |
US7358282B2 (en) * | 2003-12-05 | 2008-04-15 | Kimberly-Clark Worldwide, Inc. | Low-density, open-cell, soft, flexible, thermoplastic, absorbent foam and method of making foam |
WO2009114624A2 (en) * | 2008-03-12 | 2009-09-17 | Bluesky Medical Group Inc. | Negative pressure dressing and method of using same |
WO2009151645A2 (en) * | 2008-06-13 | 2009-12-17 | Premco Medical Systems, Inc. | Wound treatment apparatus and method |
JP5671469B2 (en) * | 2008-10-29 | 2015-02-18 | スリーエム イノベイティブ プロパティズ カンパニー | Electron curable silicone release material |
WO2014028212A2 (en) * | 2012-08-13 | 2014-02-20 | Kci Licensing, Inc. | Intelligent therapy system with evaporation management |
US20140275864A1 (en) * | 2013-03-15 | 2014-09-18 | Hydrofera, Llc | Polyurethane dressing and method for making same |
EP3288599B1 (en) * | 2015-04-25 | 2023-06-07 | Chemokind, Inc. | Wound packing material comprising chemoeffector |
EP3347068B2 (en) * | 2015-09-11 | 2024-06-12 | Smith & Nephew, Inc | Systems and methods for applying reduced negative pressure therapy |
WO2017075320A1 (en) * | 2015-10-31 | 2017-05-04 | Dermalink Technologies, Inc. | Skin adhesives, antimicrobial compositions, articles, and methods for the use thereof |
EP3522941A4 (en) * | 2016-10-05 | 2020-06-17 | 3M Innovative Properties Company | Fibrinogen composition, method and wound articles |
US11147696B2 (en) * | 2017-01-06 | 2021-10-19 | John James Scanlon | Bioresorbable scaffold having sustained drug delivery |
EP3409248B1 (en) * | 2017-06-01 | 2019-11-06 | Absorbest AB | Wound dressing |
-
2019
- 2019-10-07 US US16/602,439 patent/US20200129339A1/en not_active Abandoned
- 2019-10-07 US US16/602,440 patent/US20200129648A1/en not_active Abandoned
- 2019-10-24 US US16/602,519 patent/US20200129340A1/en not_active Abandoned
-
2023
- 2023-05-11 US US18/196,079 patent/US20230310219A1/en active Pending
- 2023-05-17 US US18/198,469 patent/US20230285197A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020114826A1 (en) * | 2001-02-21 | 2002-08-22 | Drury Thomas J. | PVA sponge with low durometer skin silicone |
US20120157750A1 (en) * | 2010-12-15 | 2012-06-21 | Timothy Mark Robinson | Targeted Delivery of Magnetically Tagged Active Agents in Combination with Negative Pressure Wound Therapy |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112998950A (en) * | 2021-03-29 | 2021-06-22 | 张梦蝶 | Medical treatment is with filler equipment of dressing sponge ring |
WO2024117756A1 (en) * | 2022-11-30 | 2024-06-06 | (주)시지바이오 | Negative pressure therapy device and method for controlling same |
Also Published As
Publication number | Publication date |
---|---|
US20200129648A1 (en) | 2020-04-30 |
US20200129339A1 (en) | 2020-04-30 |
US20230310219A1 (en) | 2023-10-05 |
US20230285197A1 (en) | 2023-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230310219A1 (en) | Wound dressing containing a vacuum pump | |
JP6026470B2 (en) | Apparatus and method for applying reduced pressure treatment to a tissue site | |
RU2428208C2 (en) | System and method of low pressure control in tissue area | |
RU2596054C2 (en) | Low pressure therapy device and methods for use thereof | |
JP5547197B2 (en) | Multilayer dressing, system, and method for applying reduced pressure to a tissue site | |
TWI558424B (en) | Dressing and method for applying reduced pressure to and collecting and storing fluid from a tissue site | |
RU2596728C2 (en) | Systems and methods of monitoring system operation for low pressure therapy | |
US20100204663A1 (en) | Wound Therapy System With Proportional Valve Mechanism | |
US20230330319A1 (en) | A negative pressure wound therapy (npwt) dressing | |
WO2021080631A1 (en) | Wound dressing containing a vacuum pump | |
US20230210699A1 (en) | A negative pressure wound therapy (npwt) dressing | |
US20230218815A1 (en) | A negative pressure wound therapy (npwt) system | |
EP3915530B1 (en) | A negative pressure wound therapy (npwt) dressing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: HYDROFERA, LLC, CONNECTICUT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HANSON, CHRISTOPHER;O'GARA, JOHN E.;DE SILVA, ALYSHA;REEL/FRAME:059451/0567 Effective date: 20211118 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
AS | Assignment |
Owner name: HYDROFERA, LLC, CONNECTICUT Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE TO ADD THE MISSING INVENTOR THOMAS J. DRURY. PREVIOUSLY RECORDED AT REEL: 059451 FRAME: 0567. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:DRURY, THOMAS J.;HANSON, CHRISTOPHER;O'GARA, JOHN E.;AND OTHERS;REEL/FRAME:061541/0131 Effective date: 20211118 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |